Published: Dec 24, 2020
HYDERABAD, India, Dec. 24, 2020 /PRNewswire/
COVAXX s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution
Agreement leverages Aurobindo s existing development, commercial and manufacturing infrastructure
Phase 2/3 clinical trials by COVAXX to begin early 1Q 2021 in Asia, Latin America and USA
Important step in ensuring equitable access and global supply during worldwide pandemic
Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN) and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children s Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.
Hauppauge, New York (Newsfile Corp. - December 24, 2020) - COVAXX, a U.S. company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo
Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets .
Aurobindo Pharma & Covaxx to develop COVID-19 vaccine for India, Unicef IANS
New Delhi; Aurobindo Pharma Limited and Covaxx, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based vaccine to fight Covid-19, for India and the UN Children’s Fund (Unicef) agency.
COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.
Commenting on the development, N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.”
Global Biosimilar Monoclonal Antibodies Market Report 2020-2030: COVID-19 Impact, Growth and Changes
ResearchAndMarkets.com s offering. Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar monoclonal antibodies market. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.
The global biosimilar monoclonal antibodies market is expected to decline from $3.21 billion in 2019 to $3.04 billion in 2020 at a compound annual growth rate (CAGR) of -5.18%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activitie